90 Day Notice for Pharmacy Utilization Management Requirements
April 01, 2021
Effective July 1, 2021, Blue Cross and Blue Shield of North Carolina (Blue Cross NC) will have changes to our pharmacy utilization management (UM) requirements.
Our UM requirements apply to all commercial members with pharmacy benefit coverage through Blue Cross NC. These changes do not affect State Health Plan, Federal Employee Program, Medicare Part D members, or any self-funded employer groups that carve out pharmacy benefits to another pharmacy benefits manager (PBM).
Below is a summary of the changes.
NEW REQUIREMENTS
lh-header-fill
true
lh-sticky-header-column
true
+-----------------------------------------------------------
| Impacted Medications +----------------------------------------------------------- | Actimmune +----------------------------------------------------------- | Advair, AirDuo, Alvesco, Anoro Ellipta, Arcapta Neohaler, | ArmonAir, Arnuity Ellipta, Asmanex, Atrovent HFA, Bevespi | Aerosphere, Breo Ellipta, Breztri, Combivent Respimat, | Duklair Pressair, Dulera, Flovent, Incruse Ellipta, | Pulmicort, QVAR, Seebri Neohaler, Serevent Diskus, | Spiriva, Stiolto, Striverdi, Symbicort, Trelegy, Tudorza, | Utibron, Wixkela +----------------------------------------------------------- | Arcalyst | +----------------------------------------------------------- | Flunisolide Nasal Spray | | +----------------------------------------------------------- | Invokana, Invokamet, Invokamet XR | | +----------------------------------------------------------- | Levocetirizine solution, Desloratadine ODT, Prevacid ODT, | Phoslyra solution | +----------------------------------------------------------- | Lidocaine-Prilocaine 2.5-2.5% | +----------------------------------------------------------- | Prolate tablets | | | +----------------------------------------------------------- | Protonix tablets, Aciphex tablets | | +----------------------------------------------------------- | Truvada 200-300mg, Descovy +-----------------------------------------------------------
Requirement
This medication will require Prior Authorization.
These medication will require Quantity Limits.
This medication will require Prior Authorization and Quantity Limits.
This medication will require Step Therapy on the Essential formulary. The preferred products will be over-the-counter intranasal steroid products.
These medications will require Step Therapy. The preferred products will be Farxiga, Jardiance, Trijardy and Xigduo XR.
hese medications will require Prior Authorization. Prior Authorization will only apply for members > 11 years of age.
This medication will require Prior Authorization, Step Therapy and Quantity Limits.
This medication will require Prior Authorization and Step Therapy. The preferred products will be oxycodone w/ acetaminophen 5-325mg, oxycodone w/ acetaminophen 7.5-325mg, or oxycodone w/ acetaminophen 10-325mg.
These medications will require Step Therapy. The preferred products will be over-the-counter proton pump inhibitors.
These medications will require Quantity Limits.
UPDATED REQUIREMENTS
lh-header-fill
true
lh-sticky-header-column
true
| Impacted Medications | Requirements | |
| Hetlioz tablets | This medication will require Step Therapy and Quantity Limits. | |
| Nefazodone, Carisoprodol, Carisoprodol/ASA, Thioridazine | The requirements of Prior Authorization and Step Therapy already on Enhanced will be added to Essential and Net Results formularies. | |
| ProAir, Proventil, Ventolin, Xopenex | The Quantity Limits of this medication will decrease from 6 inhalers per day to 2 inhalers per 30 days. | |
| Xtandi 40mg capsules | The Quantity Limits of this medication will decrease from 4 capsules per day to 3 capsules per day. |
If you have any questions, please call the Provider Blue Line℠ at 800-214-4844.